跳至主要内容
临床试验/NCT03590223
NCT03590223已完成不适用

Glycosylated Hemoglobin and the Risk of Perioperative Major Cardiovascular Events in Diabetic Patients Undergoing Coronary Bypass Revascularization

University Hospital, Basel, Switzerland1 个研究点 分布在 1 个国家目标入组 589 人开始时间: 2017年12月29日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
589
试验地点
1
主要终点
occurence of Major adverse cardiac events

研究概览

简要总结

Glycosylated Hemoglobin (HbA1c) is considered as one of the best markers to assess the glycaemia treatment over a period of 3 to 4 months, and is considered as predictive marker for perioperative mortality and morbidity. The impact of the elevated HbA1c on the risk of perioperative major cardiovascular events in patients undergoing coronary bypass revascularization (by retrospective analysis of perioperative cardiovascular events and preoperative HbA1c) is evaluated.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • patients with Diabetes mellitus undergoing coronary bypass revascularization since 2012

排除标准

  • disapproval of use of data for research purposes

结局指标

主要结局

occurence of Major adverse cardiac events

时间窗: perioperative = in hospital

myocardial infarction, cardiac related death, stroke

次要结局

  • occurence of severe renal insufficiency(perioperative = in hospital)
  • occurence of sternal wound infection(perioperative = in hospital)
  • mortality(perioperative = in hospital)

研究者

发起方
University Hospital, Basel, Switzerland
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验